ReviewMolecular biomedicine2026
FGF family in health and disease.
Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of FGF1 in Chronic Liver Diseases.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Fibroblast growth factors (FGFs) form an evolutionarily conserved signaling system that governs embryonic patterning, tissue regeneration, and systemic metabolic homeostasis. Through coordinated interactions with fibroblast growth factor receptors (FGFRs) and context-specific cofactors, FGF signaling enables precise spatial and temporal control of cellular fate and interorgan communication. While canonical FGFs coordinate local tissue dynamics, endocrine members like FGF19, FGF21, and FGF23 function as systemic hormones to regulate bile acid, glucose, and phosphate metabolism. Despite rapid advances in understanding these pathways, a unified framework that integrates their structural diversity, complex regulatory mechanisms, and the contrasting roles they play in health and disease remains fragmented. In this review, we systematically summarize the classification, structural features, and receptor specificity of the FGF family, with particular emphasis on canonical, endocrine, and intracellular FGFs. We delineate canonical and non-canonical FGF signaling pathways and their multilayered regulation by heparan sulfate proteoglycans, Klotho coreceptors, and intracellular feedback mechanisms. Furthermore, we integrate emerging insights into the roles of FGFs in organ development, tissue repair, metabolic regulation, and disease pathogenesis. A core translational insight emphasized throughout is the therapeutic duality of targeting the FGF axis: harnessing FGF agonism for tissue regeneration and metabolic regulation, versus employing FGF antagonism to block oncogenic signaling in cancer. By providing an integrated and mechanistic overview, this review clarifies key knowledge gaps and establishes a conceptual foundation for future FGF-based therapeutic innovation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.